Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor positive, HER2 low or HER2 ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca put volume heavy and directionally bearish
- AstraZeneca’s Promising Pipeline and Strategic Positioning in Lung Cancer Treatment Earns Buy Rating
- AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
- AstraZeneca announces FDA approval of Imfinzi combination
- AstraZeneca’s Calquence recommended for approval in EU for treatment of MCL